Article

TTT trial to test potential treatment for wet AMD

Mountain View, CA-IRIDEX Corp. has completed enrollment in a clinical trial for its TTT4CNV, to determine whether trans-pupillary thermotherapy (TTT) laser treatment can reduce the risk of vision loss for patients with occult wet age-related macular degeneration (AMD).

Newsletter

Don’t miss out—get Ophthalmology Times updates on the latest clinical advancements and expert interviews, straight to your inbox.

Subscribe Now!
Related Videos
(Image credit: Ophthalmology Times) CCOI's new CEO Malvina Eydelman, MD, outlines her mission and vision for the organization
CIME 2025: Neda Shamie, MD, on expanding options in pharmacological presbyopia management
At CIME 2025, Neda Shamie, MD, answers questions about Demodex blepharitis
(Image credit: Ophthalmology Times) ASCRS 2025: Deb Ristvedt, DO, on medications, lasers, and lifestyle in glaucoma management
(Image credit: Ophthalmology Times) ASCRS 2025: Mark Lobanoff, MD, on making the move to office-based surgery
Barsha Lal, PhD, discusses the way low dose atropine affects accommodative amplitude and dynamics at the 2025 ARVO meeting
(Image credit: Ophthalmology Times) NeuroOp Guru: When eye findings should prompt neuroimaging in suspected neuro-Behcet disease
Related Content
Potentially hazardous eye care products recalled nationwide
May 12th 2025

Potentially hazardous eye care products recalled nationwide

2025 Glaucoma 360 brings celebration, innovation, and education to San Francisco
December 13th 2024

California dreaming: 2025 Glaucoma 360 brings celebration, innovation, and education to San Francisco

Q&A: Carl D. Regillo, MD, shares updates on the VERONA trial for DME
May 10th 2025

Q&A: Carl D. Regillo, MD, shares updates on the VERONA trial for DME

EnVision Summit 2025: Advancing Ophthalmology and Optometry Together
November 19th 2024

Connect, learn, and innovate in a family-friendly atmosphere: What to expect at EnVision Summit 2025

Q&A: Dilsher S. Dhoot, MD, on the HELIOS trial for diabetic retinopathy
May 10th 2025

Q&A: Dilsher S. Dhoot, MD, on the HELIOS trial for diabetic retinopathy

Belantamab mafodotin–induced corneal changes in patients with multiple myeloma
May 10th 2025

Belantamab mafodotin–induced corneal changes in patients with multiple myeloma

© 2025 MJH Life Sciences

All rights reserved.